BackNovo Nordisk Overview

Novo Nordisk Long Term Debt

Track Novo Nordisk's long-term debt ($120B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$121.79B
↑ 39.50% YoYΔ $34.49B vs prior year quarter

Peer average / median

Loading

Novo Nordisk Long Term Debt History

Loading

Novo Nordisk vs. peers: Long Term Debt Comparison

Loading

Novo Nordisk Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Novo Nordisk (NVO) FAQ

As of the most recent data (June 2026), NVO shows a long-term debt of $120B. That compares with $87B in the prior-year period — up 39.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVO's long-term debt is now $120B (was $87B) — a 39.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk is outperforming or lagging.

Tracking NVO's long-term debt over time shows whether Novo Nordisk is scaling, shrinking, or reshaping that part of the business. The current reading is $120B That compares with $87B in the prior-year period — up 39.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Novo Nordisk's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $120B) with ownership activity and broader fundamentals.

Novo Nordisk's long-term debt is $120B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.